A Phase 1 interventional study of ANG-3777 (Therapeutic Dose) and ANG-3777 (Supra-therapeutic Dose) in Healthy Volunteer, sponsored by Angion Biomedica Corp. Status unknown at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-06-01.
Sponsored by Angion Biomedica Corp · Phase 1, Interventional, and Treatment
The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.
Angion Biomedica Corp is the lead sponsor of 12 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
Drug: ANG-3777 (Therapeutic Dose)
The placebo will be administered as a single dose on separate occasions intravenously as 30-minute infusions on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
Drug: Placebo
The comparator will be administered as a single dose oral Moxifloxacin Hydrochloride tablet (open-label), with a total of 240 mL of water. There will be a minimum washout of 3 days between each study drug administration.
Drug: Moxifloxacin Hydrochloride
Administered IV as a single dose on two occasions for 30 minutes on the morning of Day 1 of each treatment period (total of 4), following an 8 hour overnight fast. There will be a minimum washout of 3 days between each study drug administration.
Drug: ANG-3777 (Supra-therapeutic Dose)
Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted
Also known as: Hepatocyte growth factor mimetic
Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted
Also known as: Hepatocyte growth factor mimetic
Arms assigned to this intervention will receive normal saline, IV, Fasted
Also known as: Normal Saline
Arms assigned to this intervention will receive 400 mg, Oral, Fasted
Change from baseline in corrected QT interval by Fridericia's formula for ANG-3777 at the therapeutic and supra-therapeutic dose levels compared to placebo
Time frame: Day 1, Day 5, Day 9 and Day 13
This study is status unknown, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Angion Biomedica Corp